Genta Incorporated issued two key U.S. patents for gallium products franchise



It sounds like a science fiction movie: A killer contagion threatens the Earth, but scientists save the day with a designer drug that forces the virus to mutate itself out of existence. The killer disease? Still a fiction. The drug? It could become a reality thanks to a new study by Rice University bioengineers. The

Full Post: New analysis of the mechanisms that drive evolution in viruses and bacteria

Genta Incorporated has announced that two new patents related to the Company’s franchise in gallium-containing products have issued in the United States.

Applications similar to these patents are pending worldwide, and several additional applications that address other compositions and uses have been filed in the U.S. and other territories. These patents and filings provide for claims of compositions and uses of gallium compounds that can be taken by mouth over extended periods for treatment of skeletal diseases as well as other indications.

The two new patents, US 7,354,952B2 and US 7,456,215B2, provide for the therapeutic use of gallium complexed with various agents that increase the oral bioavailability of the active ingredient and yield superior pharmacokinetics compared with the active ingredient used alone.

G4544 is a new, clinical-stage, tablet formulation that enables oral absorption of the active ingredient contained in Ganite ? (gallium nitrate injection), a drug that is marketed by Genta and approved in the U.S. for treatment of cancer-related hypercalcemia. Genta is developing G4544 in collaboration with Emisphere Technologies, Inc. (NASDAQ: EMIS). The initial clinical study — a dose-ranging, single-dose evaluation of G4544 in normal subjects - has been completed. Genta is the IND Sponsor and is directing the clinical development program.

“The active ingredient in G4544 has shown a consistently high level of clinical activity across a range of skeletal diseases,” said Dr. Raymond P. Warrell, Jr., Chairman and Chief Executive Officer of Genta. “We believe that the emerging safety issues with long-term bisphosphonate therapy can potentially be avoided with G4544. Our goal is to establish bioequivalence to our IV drug in repeat-dose studies that may lead to rapid approval in hypercalcemia. We also foresee the potential for subsequent approvals in other diseases, such as bone metastases, Paget’s disease, and osteoporosis.”

About G4544

G4544 was developed to enable extended administration of the active ingredient in Ganite, which may greatly improve patient convenience and avoid the current need for intravenous pumps or hospitalization. The initial focus of clinical studies with G4544 will be to establish its bioequivalence with the intravenous product, potentially enabling rapid regulatory approval of the oral formulation via a 505(b)(2) application in the U.S. Genta holds or has exclusively licensed the intellectual property related to G4544.

http://www.genta.com

Link




Raptor Pharmaceuticals Corp. has announced positive results in its Phase IIa study of oral 4-methylpyrazole (”4-MP”) in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development stage of its Convivia program. Convivia is Raptor’s proprietary oral formulation of 4-MP designed to reduce systemic acetaldehyde exposure and related symptoms in ALDH2 deficient persons following

Full Post: Raptor Pharmaceuticals announces positive results for Convivia program



TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (”IND”) application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest’s proprietary abuse deterrent technology. Najib Babul, PharmD, Chief Executive Officer of

Full Post: TheraQuest’s IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA



Titan Pharmaceuticals, Inc. today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company’s method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain. Probuphine is Titan’s novel, subcutaneous implant formulation in development

Full Post: Titan Pharmaceuticals updates on Probuphine patent application



SemBioSys Genetics Inc., a biotechnology company developing protein pharmaceuticals in crop plants, has announced that it has initiated a phase I/II clinical trial of its plant-produced insulin with the first injection of its drug in humans. The trial, taking place in the United Kingdom (UK), will include up to 30 healthy volunteers in a three-arm study

Full Post: SemBioSys begins phase I/II trial of insulin produced in plant seeds



Mylan Inc. has announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company’s Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment. U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This

Full Post: Dey L.P. issued new U.S. patents for Perforomist inhalation solution